Plus Therapeutics Receives Fast Track Designation From FDA for Its Novel Glioblastoma Treatment (GlobeNewswire) - Sep 15, 2020 - "Plus Therapeutics, Inc...announced that the U.S. Food and Drug Administration (FDA) has granted the Company Fast Track designation for its lead investigational drug, Rhenium NanoLiposomes (RNL™), for the treatment of patients with recurrent glioblastoma."
Fast track designation • Brain Cancer • Glioblastoma • Oncology
|